Streetbeat News

Stock Prices

MRVL

Marvell Technology's shares are trading higher following a report from The Information suggesting that Google is planning to replace Broadcom chips with those from Marvell Technology.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:18 pm

CSCO

SPLK

Cisco has announced its plans to acquire Splunk for approximately $28 billion. This has resulted in a surge in Splunk's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:17 pm

SPLK

Trading of Splunk shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:15 pm

ARM

Arm shares are experiencing post-IPO volatility, leading to a decrease in their trading value.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:15 pm

CSCO

Cisco has announced its plan to acquire Splunk for approximately $28 billion, which has led to a decrease in Cisco's share price.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:15 pm

FDX

FedEx has reported mixed Q1 financial results and issued guidance, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:14 pm

AVGO

Broadcom's shares are trading lower following a report by The Information suggesting that Google is considering dropping Broadcom as its AI chip supplier.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:13 pm

NRXS

Neuraxis (AMEX:NRXS) reported Q2 losses of $(1.21) per share, a 39.08% decrease YoY. Sales also decreased by 5.36% to $646.00K compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:13 pm

EWU

The Bank of England has ended its streak of 14 consecutive interest rate hikes due to lower-than-expected inflation, according to CNBC. This could potentially impact the performance of the iShares MSCI United Kingdom ETF (EWU).

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:11 pm

AMTI

CYTH

Cyclo Therapeutics and Applied Molecular Transport have entered into a definitive merger agreement in an all-stock transaction. The combined company will operate under the name Cyclo Therapeutics and trade under the symbol 'CYTH'. The company will focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The company will have approximately $13.7 million cash on hand at closing to fund operations into 2H 2024. Upcoming milestones include completion of enrollment in a pivotal Phase 3 clinical trial in NPC1, reporting top line data, and preparation for NDA submission.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:08 pm